REDUCE-IT® USA Results, in Prespecified Subgroup Analyses of Landmark REDUCE-IT Global Study, Showed Robust Cardiovascular Risk Reductions Across a Variety of Study Endpoints, Including Cardiovascular Death and All-Cause Mortality

Ads

You May Also Like

miRagen Therapeutics Expands Board of Directors with Appointment of Arlene Morris

BOULDER, Colo., Jan. 05, 2018 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ:MGEN), a clinical-stage ...

Epizyme Reports Second Quarter 2017 Financial Results and Clinical and Business Progress

Key Clinical Milestones Achieved in Studies of Mesothelioma, Epithelioid Sarcoma and Pediatric Solid Tumors ...

Potential Sequential Revenue Run-Rate Growth of 30% over Q1, based on Preliminary April Results

Revenue growth accelerating as new sales initiatives and expanded team gain tractionNEW HAVEN, Conn., ...